Gastroenterology research group Publications

Publications 2019

Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, Skar V, Medhus AW, Valeur J (2019)
Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption
Gut Microbes, 1-13 (in press)
DOI 10.1080/19490976.2019.1580097, PubMed 30894059

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML (2019)
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312

Evensen H, Kristensen V, Larssen L, Sandstad O, Hauge T, Medhus AW (2019)
Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
Scand J Gastroenterol, 54 (1), 1-7
DOI 10.1080/00365521.2018.1549271, PubMed 30650313

Evensen H, Medhus AW (2019)
Response to letter to the editor: 'Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review'
Scand J Gastroenterol, 54 (4), 520
DOI 10.1080/00365521.2019.1599416, PubMed 30978123

Haraldsson E, Kylänpää L, Grönroos J, Saarela A, Toth E, Qvigstad G, Hult M, Lindström O, Laine S, Karjula H, Hauge T, Sadik R, Arnelo U (2019)
The macroscopic appearance of the major duodenal papilla influences bile duct cannulation: a prospective multicenter study by the Scandinavian Association for Digestive Endoscopy study group for ERCP
Gastrointest Endosc (in press)
DOI 10.1016/j.gie.2019.07.014, PubMed 31326385

Olesen SS, Nøjgaard C, Poulsen JL, Haas SL, Vujasinovic M, Löhr M, Lindkvist B, Bexander L, Gulbinas A, Kalaitzakis E, Ebrahim M, Erchinger F, Engjom T, Roug S, Novovic S, Hauge T, Waage A, Laukkarinen J, Parhiala M, Pukitis A, Ozola-Zālīte I, Drewes AM, Scandinavian Baltic Pancreatic Club (2019)
Chronic Pancreatitis Is Characterized by Distinct Complication Clusters That Associate With Etiological Risk Factors
Am J Gastroenterol, 114 (4), 656-664
DOI 10.14309/ajg.0000000000000147, PubMed 30741740

Safreed-Harmon K, Blach S, Aleman S, Boe Kielland K, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV (2019)
The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination
Clin Infect Dis (in press)
DOI 10.1093/cid/ciz714, PubMed 31352481

Øvrehus ALH, Midgard H (2019)
How can we achieve WHO's elimination target for hepatitis C incidence?
Lancet Gastroenterol Hepatol, 4 (6), 415-417
DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687

Ånonsen K, Sahakyan MA, Kleive D, Waage A, Verbeke C, Hauge T, Buanes T, Edwin B, Labori KJ (2019)
Trends in management and outcome of cystic pancreatic lesions - analysis of 322 cases undergoing surgical resection
Scand J Gastroenterol
DOI 10.1080/00365521.2019.1642379, PubMed 31322457

Publications 2018

Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA (2018)
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2018)
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Liver Int, 39 (1), 20-30
DOI 10.1111/liv.13949, PubMed 30157316

Engjom T, Waage A, Hoem D, Kvamme JM, Hauge T, Dimcevski G (2018)
[Chronic pancreatitis – investigation and treatment]
Tidsskr Nor Laegeforen, 138 (3)
DOI 10.4045/tidsskr.17.0341, PubMed 29411568

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M (2018)
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
J Hepatol, 68 (3), 402-411
DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808

Holme Ø, Pedersen IB, Medhus AW, Aabakken L, Glomsaker T, Kvamme JM, Løberg M, Bretthauer M, Seip B, Kjellevold Ø, Jørgensen A, Furholm S, Hoff G, de Lange T (2018)
Endoscopy assistants influence the quality of colonoscopy
Endoscopy, 50 (9), 871-877
DOI 10.1055/s-0044-101706, PubMed 29444529

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW (2018)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793

Midgard H (2018)
Hepatitis C in drug addicts
Tidsskr. Nor. Laegeforen., 138 (13), 1243

Midgard H, Kielland KB, Dalgard O (2018)
[Elimination of hepatitis C is possible]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0099, PubMed 29663789

Midgard H, Kielland KB, Dalgard O (2018)
Elimination of Hepatitis C is possible
Tidsskr. Nor. Laegeforen., 138 (7), 630-633

Publications 2017

Aghdassi AA, Schneider A, Kahl M, Schütte K, Kuliaviene I, Salacone P, Lutz J, Tukiainen E, Simon P, Schauer B, Uomo G, Hauge T, Ceyhan GO (2017)
Analysis of lifestyle factors in patients with concomitant chronic pancreatitis and liver cirrhosis
Pancreatology, 17 (5), 698-705
DOI 10.1016/j.pan.2017.07.194, PubMed 28784575

Bjørkhaug ST, Skar V, Medhus AW, Tollisen A, Bramness JG, Valeur J (2017)
Chronic alcohol overconsumption may alter gut microbial metabolism: a retrospective study of 719 ¹³C-D-xylose breath test results
Microb Ecol Health Dis, 28 (1), 1301725
DOI 10.1080/16512235.2017.1301725, PubMed 28572752

Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T (2017)
Increased hope following successful treatment for hepatitis C infection
J Adv Nurs, 74 (3), 724-733
DOI 10.1111/jan.13487, PubMed 29082540

Buer L, Høivik ML, Medhus AW, Moum B (2017)
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Dig Dis, 35 (1-2), 74-82
DOI 10.1159/000449087, PubMed 28147370

Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML (2017)
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J, ACTIVATE Study Group (2017)
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
BMC Infect Dis, 17 (1), 420
DOI 10.1186/s12879-017-2517-3, PubMed 28610605

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I et al. (2017)
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Int J Drug Policy, 47, 51-60
DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ, ACTIVATE Study Group (2017)
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Int J Drug Policy, 47, 177-186
DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134

Hellum M, Franco-Lie I, Øvstebø R, Hauge T, Henriksson CE (2017)
The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls
PLoS One, 12 (9), e0184579
DOI 10.1371/journal.pone.0184579, PubMed 28910348

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J, ACTIVATE Study Group (2017)
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Int J Drug Policy, 47, 230-238
DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998

Publications 2016

Knatten CK, Fjeld JG, Medhus AW, Pripp AH, Fyhn TJ, Aabakken L, Kjosbakken H, Edwin B, Emblem R, Bjørnland K (2016)
Preoperative liquid gastric emptying rate does not predict outcome after fundoplication
J Pediatr Surg, 52 (4), 540-543
DOI 10.1016/j.jpedsurg.2016.09.068, PubMed 28277299

Knudsen MD, de Lange T, Botteri E, Nguyen DH, Evensen H, Steen CB, Hoff G, Bernklev T, Hjartåker A, Berstad P (2016)
Favorable lifestyle before diagnosis associated with lower risk of screen-detected advanced colorectal neoplasia
World J Gastroenterol, 22 (27), 6276-86
DOI 10.3748/wjg.v22.i27.6276, PubMed 27468217

Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016)
Hepatitis C reinfection after sustained virological response
J Hepatol, 64 (5), 1020-1026
DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289

Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264

Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O (2016)
HCV epidemiology in high-risk groups and the risk of reinfection
J Hepatol, 65 (1 Suppl), S33-S45
DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987

Publications 2015

Anonsen KV, Buanes T, Rosok BI, Hauge T, Edwin B (2015)
Outcome of Laparoscopic Surgery in Patients with Cystic Lesions in the Distal Pancreas
J. Pancreas, 16 (3), 266-270

Hauge T, Hauge PW, Warloe T, Drolsum A, Johansen C, Viktil E, Aabakken L, Buanes T, Konopski Z (2015)
Randomised controlled trial of temoporfin photodynamic therapy plus chemotherapy in nonresectable biliary carcinoma--PCS Nordic study
Photodiagnosis Photodyn Ther, 13, 330-333
DOI 10.1016/j.pdpdt.2015.09.004, PubMed 26415549

Løvik A, Skodje G, Bratlie J, Brottveit M, Lundin KE (2015)
Diet adherence and gluten exposure in coeliac disease and self-reported non-coeliac gluten sensitivity
Clin Nutr, 36 (1), 275-280
DOI 10.1016/j.clnu.2015.11.017, PubMed 26714791

Otterdal K, Haukeland JW, Yndestad A, Dahl TB, Holm S, Segers FM, Gladhaug IP, Konopski Z, Damås JK, Halvorsen B, Aukrust P (2015)
Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation
Clin Transl Gastroenterol, 6, e95
DOI 10.1038/ctg.2015.23, PubMed 26133108